Facts from FDA records, not medical advice. Independent reference; not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Infections & vaccines · 2026

Hibsago (bepirovirsen)

The FDA approved Hibsago (bepirovirsen) on October 20, 2026 to treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy.
Brand name
Hibsago
Generic name
bepirovirsen
FDA approval date
October 20, 2026
Approved use (FDA wording)
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
Category on this site
Infections & vaccines

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted from FDA and openFDA records (we only tidy spacing and drop link labels). It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.